Immunome (IMNM) Free Cash Flow (2019 - 2026)
Immunome's (IMNM) quarterly Free Cash Flow came in at -$61.6 million in Q1 2026, down 8.67% YoY from -$67.5 million in Q1 2025, and down 18.65% on a QoQ basis from -$52.0 million in Q4 2025.
Immunome (IMNM) Free Cash Flow (2019 - 2026) Analysis & Trends
Immunome (IMNM) has 8 years of Free Cash Flow data on file, last reported at -$61.6 million in Q1 2026.
- Quarterly Free Cash Flow fell 8.67% year-over-year to -$61.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$205.5 million (down 26.15% YoY) and the FY2025 annual result came in at -$200.6 million, down 70.05% from the prior year.
- Free Cash Flow retreated to -$61.6 million in Q1 2026, from -$52.0 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $24.0 million in Q1 2023 to a low of -$61.6 million in Q1 2026.
- A 5-year average of -$24.5 million and a median of -$17.5 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2023 — Free Cash Flow jumped 475.27% — and 2025, when it plunged 382.15%.
- Tracing IMNM's Free Cash Flow over 5 years: stood at -$6.8 million in 2022, then slumped by 159.3% to -$17.5 million in 2023, then tumbled by 146.55% to -$43.2 million in 2024, then declined by 20.3% to -$52.0 million in 2025, then retreated by 18.65% to -$61.6 million in 2026.
- The last three Free Cash Flow figures came in at -$61.6 million (Q1 2026), -$52.0 million (Q4 2025), and -$44.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Immunome | 3.09 Bn | 2.57 Bn | - | -63.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -63.87 Mn |
| Jun 30, 2026 | -63.87 Mn |
| Mar 31, 2026 | -61.64 Mn |
| Mar 31, 2026 | -61.64 Mn |
| Dec 31, 2025 | -51.95 Mn |
| Dec 31, 2025 | -51.95 Mn |
| Sep 30, 2025 | -44.91 Mn |
| Sep 30, 2025 | -44.91 Mn |
| Jun 30, 2025 | -47.02 Mn |
| Jun 30, 2025 | -47.02 Mn |
| Mar 31, 2025 | -56.72 Mn |
| Mar 31, 2025 | -56.72 Mn |
| Dec 31, 2024 | -43.19 Mn |
| Dec 31, 2024 | -43.19 Mn |
| Sep 30, 2024 | -35.71 Mn |
| Sep 30, 2024 | -35.71 Mn |
| Jun 30, 2024 | -27.31 Mn |
| Jun 30, 2024 | -27.31 Mn |
| Mar 31, 2024 | -11.76 Mn |
| Mar 31, 2024 | -11.76 Mn |